DZHK financed and Associated Studies

Validation of Cardiovascular Magnetic Resonance against Invasive Haemodynamics in Patients with Heart Failure with Preserved Ejection Fraction (Decipher HFpEF-DZHK12)

The DECIPHER HFpEF-DZHK12 study investigates whether diastolic heart failure can be better diagnosed and its causes clarified with the help of cardiovascular magnetic resonance imaging (CMR). In the case of a positive outcome, the study would lead to a modification of the guidelines for diagnosing heart failure with preserved ejection fraction (HFpEF).

The problem with HFpEF is that the left ventricle is stiff and does not sufficiently fill with blood. With the non-invasive methods currently used, such as an ultrasound examination, this is hard to measure and is often only identified late. The study compares the CMR data with the results of the present gold standard in the diagnosis of HFpEF, invasive hemodynamics, where patients are examined using a cardiac catheter. In order to obtain a comprehensive picture of the validity of CMR, the study compares the CMR measurements with the results of ultrasound examinations and analyses of myocardial tissue samples.

Using these data, the researchers aim to investigate whether CMR can help clarify why the disease arises, especially since the underlying cause of diastolic heart failure can vary greatly. For example, it can be caused by an inflammation of the heart muscle (myocardium), thickening of the myocardium, or decreased blood flow to the myocardium due to changes to the smallest blood vessels.

CMR procedures developed in recent years enable these parameters to be assessed and are for the first time merged in a combined examination in the study. This is because, unlike an ultrasound examination, these new procedures can not only measure the flow and filling of the ventricle, but also see, whether the heart muscle is inflamed, whether there is a pathological proliferation of the connective tissue, or whether there is a change to the small vessels.

Significant therapeutic studies are only possible once we can distinguish between the various patient subgroups. DECIPHER HFpEF-DZHK12 aims to lay the foundation for this. It is the first multicentre study on the diagnosis of HFpEF worldwide. Beside Frankfurt am Main, the DZHK sites in Berlin, Heidelberg, Göttingen, and Bad Nauheim are also participating.

More information:
http://www.cardiac-imaging.org/decipher--hfpef.html

Decipher HFpEF-DZHK12 - Validation of Cardiovascular Magnetic Resonance against Invasive Haemodynamics in Patients with Heart Failure with Preserved Ejection Fraction (Decipher HFpEF-DZHK12)

Publications

There are no publications available yet.

Principal Investigators

Principal investigator: Eike Nagel (Frankfurt)

Press releases and news

09.10.2017
 

Study recruitment is available in these cities

The map only displays recruitment locations within Germany.

Study information
Decipher HFpEF-DZHK12

Recruiting status
Study completed
Recruitment start
01.2018
Patients
170
185
Clinical Trials Registrierung

NCT03251183

Category
Early clinical study
DZHK Funding
€ 810.624
Links
https://www.cardiac-imaging.org/decipher--hfpef.html

Operative contact:
Franziska Weis
Franziska.Weis@kgu.de

Studienzentren/Kontakt (PDF)

Do you want to associate your clinical trial with us?

Clinical studies that are not DZHK-financed can receive the status "DZHK-associated" if their objectives match our research interest. By associating, we support the study ideally, for example, by promoting recruitment through our network.

Please contact clinicalstudies@dzhk.de for further information.

Study Participation

Would you like to participate in a DZHK study or learn more about our clinical studies? The Patient Information Platform (PIP) informs patients, relatives and interested individuals about our clinical studies.

Learn more (German only)

Contact

Alexandra Klatt
Coordinator Clinical Research
Phone: +49 (0)30 3465 529 10 
alexandra.klatt@dzhk.de